Loading...

News Update: GlaxoSmithkline Amends Licensing Deal with Denmark's Genmab

279 views

Loading...

Loading...

Transcript

The interactive transcript could not be loaded.

Loading...

Loading...

Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Uploaded on Jul 1, 2010

Jul 1, 2010 -- GlaxoSmithkline (GSK) is lower after the drug giant said it had amended a licensing agreement with Denmark's Genmab for their Arzerra cancer drug in a way that will have a "material impact" on Genmab's 2010 prospects, Reuters reports.

GlaxoSmithKline shares are down $0.22, or 0.65%, to $33.

Loading...

When autoplay is enabled, a suggested video will automatically play next.

Up next


to add this to Watch Later

Add to

Loading playlists...